U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 11 - 20 of 448 results

Status:
Investigational
Source:
NCT00114790: Phase 1/Phase 2 Interventional Completed Head and Neck Cancer
(2003)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Status:
Investigational
Source:
INN:efepristin
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Efepristin (RPR 106972) is an oral streptogramin consisting of two synergistic components RPR 112808 (pristinamycin IB) and RPR 106950 (pristinamycin IIB). It demonstrated activity against Gram-positive microorganisms in vitro and in vivo, including those with multi-drug resistance. The streptogramins inhibit bacterial growth by disrupting the translation of mRNA into protein.

Showing 11 - 20 of 448 results